

PRAK (A-7): sc-46667

BACKGROUND

PRAK (p38-regulated/activated kinase), also referred to as mitogen-activated protein kinase (MAPK)-activated protein kinase (MAPKAPK)-5, is an ubiquitously expressed serine/threonine kinase regulated by p38 α and p38 β MAP kinases. Activated JNK, p38 γ or p38 δ are unable to induce phosphorylation of PRAK *in vitro*. Phosphorylation of PRAK occurs *in vivo* in response to p38 activation by stress-related extracellular stimuli including UV light, oxidation and proinflammatory cytokines. Two other substrates for p38, MAPKAPK-2 and MAPKAPK-3/3pK, share approximately 45% sequence homology with PRAK including the phosphorylation motif recognized by p38, Lys-X-Thr-Pro. Activated PRAK has been shown to specifically phosphorylate HSP 27 *in vitro*, suggesting that the protein may play a role in stress-induced small heat shock protein phosphorylation *in vivo*.

CHROMOSOMAL LOCATION

Genetic locus: MAPKAPK5 (human) mapping to 12q24.12; Mapkapk5 (mouse) mapping to 5 F.

SOURCE

PRAK (A-7) is a mouse monoclonal antibody raised against amino acids 294-473 mapping at the C-terminus of PRAK of human origin.

PRODUCT

Each vial contains 200 μ g IgG $_1$ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

PRAK (A-7) is available conjugated to agarose (sc-46667 AC), 500 μ g/0.25 ml agarose in 1 ml, for IP; to HRP (sc-46667 HRP), 200 μ g/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-46667 PE), fluorescein (sc-46667 FITC), Alexa Fluor[®] 488 (sc-46667 AF488), Alexa Fluor[®] 546 (sc-46667 AF546), Alexa Fluor[®] 594 (sc-46667 AF594) or Alexa Fluor[®] 647 (sc-46667 AF647), 200 μ g/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor[®] 680 (sc-46667 AF680) or Alexa Fluor[®] 790 (sc-46667 AF790), 200 μ g/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor[®] is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

PRAK (A-7) is recommended for detection of PRAK of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:200-1:2000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for PRAK siRNA (h): sc-36310, PRAK siRNA (m): sc-36311, PRAK shRNA Plasmid (h): sc-36310-SH, PRAK shRNA Plasmid (m): sc-36311-SH, PRAK shRNA (h) Lentiviral Particles: sc-36310-V and PRAK shRNA (m) Lentiviral Particles: sc-36311-V.


Molecular Weight of PRAK: 54 kDa.

Positive Controls: NIH/3T3 whole cell lysate: sc-2210, Sol8 cell lysate: sc-2249 or C6 whole cell lysate: sc-364373.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



PRAK (A-7): sc-46667. Western blot analysis of PRAK expression in A-431 (A), WI-38 (B), NIH/3T3 (C), Sol8 (D), NRK (E) and C6 (F) whole cell lysates.



PRAK (A-7): sc-46667. Immunoperoxidase staining of formalin fixed, paraffin-embedded human stomach tissue showing cytoplasmic and nuclear staining of glandular cells. Kindly provided by The Swedish Human Protein Atlas (HPA) program.

SELECT PRODUCT CITATIONS

- Aberg, E., et al. 2006. Regulation of MAPK-activated protein kinase 5 activity and subcellular localization by the atypical MAPK ERK 4/MAPK4. *J. Biol. Chem.* 281: 35499-35510.
- Aberg, E., et al. 2009. Docking of PRAK/MK5 to the atypical MAPKs ERK3 and ERK4 defines a novel MAPK interaction motif. *J. Biol. Chem.* 284: 19392-19401.
- Dingar, D., et al. 2010. Characterization of the expression and regulation of MK5 in the murine ventricular myocardium. *Cell. Signal.* 22: 1063-1075.
- De la Mota-Peynado, A., et al. 2011. Identification of the atypical MAPK Erk3 as a novel substrate for p21-activated kinase (Pak) activity. *J. Biol. Chem.* 286: 13603-13611.
- Menon, M.B., et al. 2013. Endoplasmic reticulum-associated ubiquitin-conjugating enzyme Ube2j1 is a novel substrate of MK2 (MAPKAP kinase-2) involved in MK2-mediated TNF α production. *Biochem. J.* 456: 163-172.
- Marquis, M., et al. 2014. The non-classical MAP kinase ERK3 controls T cell activation. *PLoS ONE* 9: e86681.
- Al-Mahdi, R., et al. 2015. A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration. *Cell Adh. Migr.* 9: 483-494.
- Shrestha, A., et al. 2020. Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38MAPK-MK2 axis and affects NF κ B-mediated transcription. *Sci. Rep.* 10: 11388.
- Khalil, M.I., et al. 2022. The TLK1-MK5 axis regulates motility, invasion, and metastasis of prostate cancer cells. *Cancers* 14: 5728.

RESEARCH USE

For research use only, not for use in diagnostic procedures.